Skip to main content

Advertisement

SpringerLink
Log in

Alteration of cardiovascular risk parameters in women with polycystic ovary syndrome who were prescribed to ethinyl estradiol–cyproterone acetate

  • General Gynecology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Purpose

We aimed to evaluate the alteration of cardiovascular and metabolic risk parameters of polycystic ovary syndrome (PCOS) patients after a 6-month treatment with an oral contraceptive (OC) containing cyproterone acetate (CPA).

Methods

Forty women with PCOS were evaluated at baseline and after treatment with an OC. Carotid intima-media thickness (CIMT), brachial artery flow-mediated dilatation (FMD), nitrate-mediated dilatation (NMD), high sensitive (hs)-CRP, lipid levels, index of glucose sensitivity, and homeostasis model assessment of insulin resistance index (HOMA) were assessed.

Results

Mean CIMT was significantly elevated (0.03 ± 0.01 mm) (p < 0.05). There was a tendency of reduction in FMD, which was significant among overweight patients (p < 0.05). Total cholesterol, low-density lipid (LDL), and triglyceride levels were significantly elevated (p < 0.05).

Conclusion

CIMT as an indicator of early atherosclerosis and FMD as a finding of endothelial dysfunction seem to be deteriorated especially in overweight PCOS patients who were prescribed to OC containing cyproterone acetate for 6 months.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yıldız BO (2004) The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89:2745–2749

    Article  PubMed  CAS  Google Scholar 

  2. ACOG Practice Bulletin (2009) Clinical management guidelines for obstetrician–gynecologists: polycystic ovary syndrome. Obstet Gynecol 114:936–949

    Article  Google Scholar 

  3. Mak W, Dokras A (2009) Polycystic ovarian syndrome and the risk of cardiovascular disease and thrombosis. Semin Thromb Hemost 35(7):613–620

    Article  PubMed  CAS  Google Scholar 

  4. Vrbikova J, Cibula D (2005) Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update 11:277–291

    Article  PubMed  CAS  Google Scholar 

  5. Nader S, Diamanti-Kandarakis E (2007) Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Hum Reprod 22:317–322

    Article  PubMed  CAS  Google Scholar 

  6. Yildiz BO (2008) Oral contaceptives in polycystic ovary syndrome: risk-benefit assesment. Semin Reprod Med 26:111–120

    Article  PubMed  Google Scholar 

  7. Baillargeon JP, McClish DK, Essah PA, Nestler JE (2005) Association between the current use of low-dose oral contraceptives and cadiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 90:3863–3870

    Article  PubMed  CAS  Google Scholar 

  8. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M (2007) Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115:459–467

    Article  PubMed  Google Scholar 

  9. Juonala M, Viikari J, Laitinen T, Marniemi J, Helenius H, Ronnemaa T, Raitakari OT (2004) Interrelations between brachial endothelial function and carotid intima-media thickness in young adults. Circulation 110:2918–2923

    Article  PubMed  Google Scholar 

  10. Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, Blumenfeld Z (2004) Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 89:2160–2165

    Article  PubMed  CAS  Google Scholar 

  11. Lakhani K, Hardiman P, Seifalian AM (2004) Intima-media thickness of elastic and muscular arteries of young women with polycystic ovaries. Atherosclerosis 175:353–359

    Article  PubMed  CAS  Google Scholar 

  12. Orio F, Palomba S, Cascella T, Simone BD, Biase SD, Russo T, Labella D, Zullo F, Lombardi G, Colao A (2004) Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 89:4588–4593

    Article  PubMed  CAS  Google Scholar 

  13. Carmina E, Orio F, Palombo S, Longo R, Cascella T, Lombardi G, Rini GB, Lobo RA (2006) Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am J Med 119:356.e 1–356.e 6

    Article  CAS  Google Scholar 

  14. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N (2001) Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 86:2453–2455

    Article  PubMed  CAS  Google Scholar 

  15. Rotterdam ESHRE/ASRM-sponsored PCOS Concensus Workshop Group (2004) Revised 2003 concensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19–25

    Google Scholar 

  16. Legro RS, Kunselman AR, Dodson WC, Dunaif A (1999) Prevalance and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84:165–169

    Article  PubMed  CAS  Google Scholar 

  17. Birdsall MA, Farquhar CM, White HD (1997) Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catherization. Ann Intern Med 126:32–35

    PubMed  CAS  Google Scholar 

  18. Meyer C, McGrath BP, Teede HJ (2007) Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 30:471–478

    Article  PubMed  CAS  Google Scholar 

  19. Battaglia C, Mancini F, Fabbri R, Persico N, Busacchi P, Facchinetti F, Venturoli S (2010) Polycystic ovary syndrome and cardiovascular risk in young patients treated with drosperinone–ethinylestradiol or contraceptive vaginal ring. A prospective, randomized, pilot study. Fertil Steril 94(4):1417–1425

    Article  PubMed  CAS  Google Scholar 

  20. Luque-Ramirez ML, Mendieta-Azcona C, Alverez-Blasco F, Escobar-Morreale HF (2009) Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome. Fertil Steril 91:2527–2536

    Article  PubMed  CAS  Google Scholar 

  21. Mancini F, Cianciosi A, Persico N, Facchinetti F, Busacchi P, Battaglia C (2010) Drospirenone and cardiovascular risk in lean and obese polycystic ovary syndrome patients: a pilot study. Am J Obstet Gynecol 202(2):169.e1–169.e8

    Article  Google Scholar 

  22. Buchner NJ, Rump LC (2003) Oral contraceptives and endothelial function: harm or benefit? J Hypertens 21:2227–2230

    Article  PubMed  CAS  Google Scholar 

  23. Tarkun I, Arslan BC, Canturk Z, Turemen E, Sahin T, Duman C (2004) Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 89:5592–5596

    Article  PubMed  CAS  Google Scholar 

  24. Virdis A, Pinto S, Versari D, Salvetti G, Bernini G, Fruzetti F, Genazzani AR, Taddei S, Salvetti A (2003) Effect of oral contraceptives on endothelial function in the peripheral microcirculation of healthy women. J Hypertens 21:2275–2280

    Article  PubMed  CAS  Google Scholar 

  25. Lizarelli PM, Martins WP, Vieira CS, Soares GM, Franceschini SA, Ferriani RA, Patta MC (2009) Both a combined oral contraceptive and depot medroxyprogesterone acetate impair endothelial function in young women. Contraception 79:35–40

    Article  PubMed  CAS  Google Scholar 

  26. Vural B, Calıskan E, Turkoz E, Kilic T, Demirci A (2005) Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Hum Reprod 20:2409–2413

    Article  PubMed  Google Scholar 

  27. Mancini F, Cianciosi A, Reggiani GM, Facchinetti F, Battaglia C, Aloysio D (2009) Endothelial function and its relation to leptin, homocysteine, and insulin resistance in normalweight and overweight eumenorrheic women and PCOS patients: a pilot study. Fertil Steril 91:2537–2544

    Article  PubMed  CAS  Google Scholar 

  28. Karasek D, Vaverkova H, Halenka M, Budikova M, Novoty D (2006) Brachial endothelial function in subjects with familial combined hyperlipidemiaand its relationships to carotid artery intima-media thickness. Int Angiol 25:418–426

    PubMed  CAS  Google Scholar 

  29. Johnson HM, Douglas PS, Srinivasan SR, Bond MG, Tang R, Li S, Chen W, Berenson GS, Stein JH (2007) Predictors of carotid intima media thickness progression in young adults: the Bogalusa Heart Study. Stroke 38:900–905

    Article  PubMed  Google Scholar 

  30. Diamanti-Kandarakis E, Kandarki E, Christakou C, Panidis D (2009) The effect of pharmaceutical intervention on lipid profile in polycystic ovary syndrome. Obes Rev 10:431–441

    Article  PubMed  CAS  Google Scholar 

  31. Soares GM, Vieira CS, Martin W, Dos Reis RM, de Sa MF, Ferriani RA (2009) Metabolic and cardiovascular impact of oral contraceptives in polycystic ovary syndrome. Int J Clin Pract 63:160–169

    Article  PubMed  CAS  Google Scholar 

  32. Culberg G, Hamberger L, Mattsson LA, Mobacken H, Samsioe G (1985) Lipid metabolic studies studies in women with a polycystic ovary syndrome during treatment with a low dose desogestrel–ethinyl estradiol combination. Acta Obstet Gynecol Scand 64:203–207

    Article  Google Scholar 

  33. Korytkowski MT, Mokan M, Horwitz MJ, Sl Berga (1995) Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrinol Metab 80:3327–3334

    Article  PubMed  CAS  Google Scholar 

  34. Guido M, Romualdi D, Giuliani M, Suriano R, Selvaggi L, Apa R, Lanzone A (2004) Drosperinone for the treatment hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 89:2817–2823

    Article  PubMed  CAS  Google Scholar 

  35. Prelevic GM, Würzburger MI, Trpkovic D, Balint-Peric L (1990) Effects of a low dose estrogen–anti-androgen combination (Diana-35) on lipid and carbohydrate metabolism in patients with polycystic ovary syndrome. Gynecol Endocrinol 4:157–168

    Article  PubMed  CAS  Google Scholar 

  36. Luque-Ramirez M, Alvarez-Blasco F, Botella-Carretero JI, Martinez–Bermejo E, Lasuncion MA, Escobar-Morreale HF (2007) Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 92:2453–2461

    Article  PubMed  CAS  Google Scholar 

  37. Elter K, Imir G, Durmusoglu F (2002) Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod 17:1729–1737

    Article  PubMed  CAS  Google Scholar 

  38. Cauci S, Santolo MD, Culhane JF, Stel G, Gonano F, Guaschino S (2008) Effects of third-generation oral contraceptives on high-sensitivity C-reactive protein and homocysteine in young women. Obstet Gynecol 111:857–864

    Article  PubMed  CAS  Google Scholar 

  39. Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS (2008) The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab 93:4299–4306

    Article  PubMed  CAS  Google Scholar 

  40. Buchbinder S, Kratzsch J, Fiedler GM, Yar V, Brügel M, Leichtle A, Weber W, Alexander H, Matthes G, Thiery J (2008) Body weight and oral contraceptives are the most important modulators of serum CRP levels. Scand J Clin Lab Invest 68:140–144

    Article  PubMed  CAS  Google Scholar 

  41. Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, Baron AD (2001) Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 103:1410–1415

    PubMed  CAS  Google Scholar 

  42. Soares GM, Vieira CS, Martins WP, Fraceschini SA, Reis RM, Silva de Sa MF, Ferriani RA (2009) Increased arterial stiffness in nonobese women with polycystic ovary syndrome (PCOS) without comorbidities: one more characteristic inherent to the syndrome? Clin Endocrinol 71:406–411

    Article  CAS  Google Scholar 

  43. Luque-Ramirez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar-Morreale HF (2007) Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. Hum Reprod 22:3197–3203

    Article  PubMed  CAS  Google Scholar 

  44. Meyer C, McGrath BP, Cameron J, Kostsopoulos D, Teede HJ (2005) Vascular dysfunction and metabolic parameters in polycystic ovary syndrome. J Clin Endocrinol Metab 90:4630–4635

    Article  PubMed  CAS  Google Scholar 

  45. Deugarte CM, Bartolucci AA, Azziz R (2005) Prevalance of insulin resistance in the polycystic ovary syndrome using the homeostasis model assesment. Fertil Steril 83:1454–1460

    Article  PubMed  CAS  Google Scholar 

  46. Cibula D, Fanta M, Vrbikova J, Stanicka S, Dvorakova K, Hill M, Skhra J, Zivny J, Skrenkova J (2005) The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenemia, SHBG and lipids in PCOS patients. Hum Reprod 20:180–184

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None of the authors has any conflict of interest, financial or otherwise.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Dokuz Eylul University Medical School, Dokuz Eylul University Hospital, 35210, Balcova, Izmir, Turkey

    Funda Gode, Cemal Posaci, Bahadir Saatli & Didem Uysal

  2. Department of Radiology, Dokuz Eylul University Medical School, Izmir, Turkey

    Cigdem Karagoz & Mustafa Secil

  3. Department of Cardiology, Dokuz Eylul University Medical School, Izmir, Turkey

    Bahri Akdeniz

Authors
  1. Funda Gode
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cigdem Karagoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cemal Posaci
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bahadir Saatli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Didem Uysal
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mustafa Secil
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bahri Akdeniz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Funda Gode.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gode, F., Karagoz, C., Posaci, C. et al. Alteration of cardiovascular risk parameters in women with polycystic ovary syndrome who were prescribed to ethinyl estradiol–cyproterone acetate. Arch Gynecol Obstet 284, 923–929 (2011). https://doi.org/10.1007/s00404-010-1790-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-010-1790-9

Keywords

Search

Navigation